Feb 12 (Reuters) - CSL Ltd (CSL) :
- TOP-LINE RESULTS FROM PHASE 3 AEGIS-II TRIAL EVALUATING EFFICACY AND SAFETY OF CSL112
- THERE WERE NO MAJOR SAFETY OR TOLERABILITY CONCERNS WITH CSL112
- STUDY DID NOT MEET ITS PRIMARY EFFICACY ENDPOINT OF MACE REDUCTION AT 90 DAYS
News: CSL CSL Says Top-Line Results From Phase 3 Aegis-II Trial Evaluating Efficacy And Safety Of...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$255.97 |
Change
7.580(3.05%) |
Mkt cap ! $124.0B | |||
| Open | High | Low | Value | Volume |
| $252.00 | $256.22 | $251.10 | $227.4M | 882.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 123 | $255.96 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $255.98 | 119 | 15 |
View Market Depth
| Last trade - 12.52pm 18/07/2025 (20 minute delay) ? |
| CSL (ASX) Chart |